-
StockNews.com Begins Coverage on CytRx (NASDAQ:CYTR)
18 Sep 2022 08:07 GMT
… rating on the stock.
CytRx Price Performance
NASDAQ:CYTR opened … the quarter.
About CytRx
(Get Rating)
CytRx Corporation, a biopharmaceutical … of novel anti-cancer drug candidates that employ novel … analysts' ratings for CytRx and related companies with …
-
European Patent Office Awards CytRx Key Patent
07 Sep 2022 13:49 GMT
… CytRx has also pursued patent protection covering certain specific drugs … LADR system and of drugs incorporating the LADR system. … of LADR and the drugs that result from combining … ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold …
-
CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors
09 Aug 2022 12:40 GMT
… licensed drug Aldoxorubicin to the next-gen LADR drugs … events or otherwise.
About CytRx
CytRx Corporation (OTCQB: CYTR) … with cancer. CytRx’s most recent advanced drug conjugate, aldoxorubicin … Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold …
-
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
19 May 2022 21:23 GMT
… uncertain and outside of CytRx’s control. Forward- … events or otherwise.
About CytRx
CytRx Corporation (OTCQB: CYTR) is … with cancer. CytRx’s most recent advanced drug conjugate, aldoxorubicin, … Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold …
-
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
17 May 2022 12:30 GMT
… , future events or otherwise.
About CytRx
CytRx Corporation (OTCQB: CYTR) is a … patients with cancer. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is … ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to …
-
CytRx Partners with Oncology Development Expert to Advance LADR Platform
20 Apr 2022 12:15 GMT
… developing its next-generation LADR drugs toward first-in-human clinical … next-generation LADR drugs closer to saving lives. CytRx is committed to … ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to …
-
CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress
21 Mar 2022 12:00 GMT
… lives by making cancer drugs work better with an … Our next-generation LADR drugs have undergone extensive testing and … our next-generation LADR drugs to human clinical trials. … ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold …
-
CytRx to absorb subsidiary Centurion BioPharma; former CEO retires from board
09 Mar 2022 18:38 GMT
… terminated. CytRx CEO Stephen Snowdy said the LADR drug, Aldoxorubicin … possible for the LADR drugs. Additionally, the Company … Snowdy. In addition, CytRx said Chairman Louis Ignarro will … immediately. Kriegsman served as CytRx’s Chairman, President and …
-
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C
24 Feb 2022 13:00 GMT
… our LADRTM technology."
About CytRx
CytRx Corporation (OTCQB: CYTR) is a … and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is … ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to …
-
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C
14 Feb 2022 13:00 GMT
… licensing deal with Orphazyme.
About CytRx
CytRx Corporation (OTCQB: CYTR) is a … and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is … ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to …
About
© 1995-2025